The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of COVID-19 on clinical cancer care: An individual-patient level analysis.
 
Lynsey M Drewett
No Relationships to Disclose
 
Sian Alexandra Pugh
No Relationships to Disclose
 
Rosalind Kieran
No Relationships to Disclose
 
Binu Nair
No Relationships to Disclose
 
Hossameldin Attia
No Relationships to Disclose
 
Muhammad Iftikhar Sabar
No Relationships to Disclose
 
Isabel Milne
Honoraria - Pierre Fabre
 
Sharon Saunders
Travel, Accommodations, Expenses - Pfizer
 
Jennie Bragg
Travel, Accommodations, Expenses - Novartis
 
Deborah Whitehorn
No Relationships to Disclose
 
Jonathan Lay
No Relationships to Disclose
 
Oscar M Rueda
No Relationships to Disclose
 
Fiona Harris
No Relationships to Disclose
 
Sarah Joanne Welsh
No Relationships to Disclose
 
Gary Doherty
Honoraria - AstraZeneca; Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; MSD; Novartis; Pfizer; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Bristi Basu
Consulting or Advisory Role - Eisai (Inst); GenMab (Inst); Roche (Inst)
Speakers' Bureau - Eisai Europe; Eisai Europe (Inst)
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Roche
 
Jean Abraham
Research Funding - AstraZeneca/MedImmune
 
Emma Beddowes
No Relationships to Disclose
 
Philippa Gail Corrie
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Microbiotica; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Halozyme (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Brent O'Carrigan
No Relationships to Disclose